Eli Lilly’s obesity drug Zepbound approved to treat sleep apnea in U.S.

The Meals and Drug Administration on Friday cleared Eli Lilly’s weight problems drug Zepbound as the primary remedy for a standard sleep problem within the U.S.

Zepbound, whose scientific title is tirzepatide, has now been particularly authorized for sufferers with each weight problems and moderate-to-severe obstructive sleep apnea, or OSA, a situation characterised by respiration interruptions throughout sleep.

That is the primary time that Zepbound has been authorized for a sign apart from weight reduction, which might assist it acquire wider insurance coverage protection.